Quantification of risk factors for postherpetic neuralgia in herpes zoster patients

Neurology

Volumn 87, Issue 1, 2016, Pages 94-102

  Forbes, Harriet J ^a   Bhaskaran, Krishnan ^a   Thomas, Sara L ^a   Smeeth, Liam ^a   Clayton, Tim ^a   Mansfield, Kathryn ^a   Minassian, Caroline ^a   Langan, Sinéad M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; ASTHMA; BODY MASS; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DRUG MEGADOSE; DRUG USE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INVESTIGATIVE PROCEDURES; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERSONALITY DISORDER; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; SOCIAL STATUS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNDERWEIGHT; COMPLICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNOSUPPRESSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEURALGIA, POSTHERPETIC; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84977534269     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002808     Document Type: Article

References (35)

1. Dworkin RH, Schmader KE, Goldstein EJC. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36: 877-882
2. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc 2007; 107(suppl 1): S2-S7
3. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004; 4: 26-33
4. Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J 2010; 182: 1731-1736
5. Sacks GM. Unmet need in the treatment of postherpetic neuralgia. Am J Manag Care 2013; 19(1 suppl): S207-S213
6. Harpaz R, Nagel MA, Schmader K, et al. Roundtable on postherpetic neuralgia: what, why, how long, and what's next?. Popul Health Manag 2012; 15: 385-390
7. Johnson RW, Rice ASC. Postherpetic neuralgia. New Engl J Med 2014; 371: 1526-1533
8. Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014; 2: CD006866
9. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New Engl J Med 2005; 352: 2271-2284
10. Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30-54
11. Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain 2016; 157: 30-54
12. Cohen JI. Herpes zoster. New Engl J Med 2013; 369: 255-263
13. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 2015; 44: 827-836
14. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based casecontrol study. BMJ 2014; 348: g2911
15. Klompas M, Kulldorff M, Vilk Y, et al. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc 2011; 86: 1146-1153
16. Forbes HJ, Thomas SL, Smeeth L, Langan SM. Prescription of antiviral therapy after herpes zoster in general practice: who receives therapy?. Br J Gen Pract 2012; 62: e808-e814
17. World Health Organisation. Background Paper: Herpes Zoster Vaccines. SAGE Working Group on Varicella and Herpes Zoster Vaccines. Geneva: World Health Organisation; 2014
18. Public Health England. Vaccine Update: Issue 213, March 2014. 2014. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/287657/213- March2014-08-accessible.pdf. Accessed January 19, 2016
19. NHS. Investing in General Practice: The New General Medical Services Contract. Annex A: Quality Indicators: Summary of Points. 2004. Available at: http://www.nhsemployers.org/;/media/Employers/Documents/SiteCollectionDocuments/gms-contract-cd-130209.pdf. Accessed January 20, 2016
20. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011; 30: 377-399
21. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-2096
22. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321: 794-796
23. Baron R, Haendler G, Schulte H. Afferent large fiber polyneuropathy predicts the development of postherpetic neuralgia. Pain 1997; 73: 231-238
24. Opstelten W, Mauritz JW, De Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002; 19: 471-475
25. Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clinic Proc 2007; 82: 1341-1349
26. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3: 335-342
27. Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009; 137: 38-47
28. Parruti G, Tontodonati M, Rebuzzi C, et al. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking, trauma and antiviral therapy. BMC Med 2010; 8: 58
29. Bouhassira D, Chassany O, Gaillat J, et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice. Pain 2012; 153: 342-349
30. Katz J, McDermott MP, Cooper EM, et al. Psychosocial risk factors for postherpetic neuralgia: a prospective study of patients with herpes zoster. J Pain 2005; 6: 782-790
31. Opstelten W, Zuithoff NPA, van Essen GA, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132(suppl 1): S52-S59
32. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 1308-1314
33. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678-682
34. Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009; 89: 612-616
35. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996; 9: 361-381